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INTRODUCTION
Hepatitis A virus (HAV) infection is a global 
disease caused by a picornavirus transmitted 
via the fecal-oral route, by person-to-person 
contact, or ingestion of contaminated food 
or water. Most infections are asymptomatic 
in children under 6 years of age, whereas this 
infection is usually symptomatic among older 
children and adults, with signs and symptoms 
that usually last less than 2 months. The case-
fatality rate for fulminant hepatitis A among 
persons of all ages is approximately 0.3%.1
Hepatitis A (HA) is a very common in-
fection of the early years of life in developing 
countries of Asia, Africa, and Latin America, 
where seroprevalence rates approach 100% 
and most infections occur by 5 years of age.2 
However, in several geographic areas, there 
have been changes in the epidemiology of HA, 
such as Southeast Asia and China. A number of 
countries have shifted from high to intermedi-
ate and from intermediate to low endemicity, 
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mended. In Brazil, mainly in the South and Southeast regions, the epidemiology of hepatitis A (HA) 
has shifted from high to intermediate endemicity, which would have implication on policy of 
HA vaccination for these populations. Objective: To verify the prevalence of HA immunity in adult 
patients with liver cirrhosis (LC), in Uberlândia MG, a city of Southeastern Brazil. Methods: Be-
tween December 2005 and December 2006, 106 patients with LC were consecutively evaluated. In 
addition, 75 individuals without LC or alcoholism were evaluated (control group - CG). Results: 
Total anti-HAV (ELISA methods) was positive in 104 (98.1%) patients with LC (82 men, 24 women; 
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as a result of advances in hygiene, sanitation 
and the quality of drinking water, reflecting 
improvements in living standards and socio-
economic progress.3 
In Brazil, a multicenter study found in-
termediate endemicities in the Southern and 
Southeastern regions (anti-HAV prevalence 
rates of 55.7%) and in the Northeastern region 
(76.5%) and high endemicity in the Northern 
region (92.8%).4 In other studies performed 
in cities of Southeastern Brazil, the following 
seroprevalences of anti-HAV were observed: 
32.1% in individuals aged between 1 and 23 
years, in Rio de Janeiro, RJ;5 38.6% in children 
aged between 4 and 14 years, in Vila Velha, 
ES;6 and 54.2% in adolescents aged between 
10.4 and 19.9 years, in São Paulo, SP.7 Lower 
exposure to HAV in childhood causes adults 
to be vulnerable to such infection, when the 
disease has a higher morbidity. The case-fa-
tality rate for fulminant HA is 1.8% among 
adults older than 50 years.1
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Although not at increased risk for HAV infection, per-
sons who have chronic liver disease are at increased risk for 
fulminant HA, with a higher fatality rate.1 During a large 
outbreak of HA that took place in Shanghai, China, in the 
late 1980s, a 5.6-fold higher fatality rate was reported among 
chronic HBsAg carriers than among patients without HBV 
infection. In addition, in the United States, between 1983 
and 1988, a total of 115,551 cases of acute HA were reported 
to the Centers for Disease Control and Prevention (CDC) 
and a 58.5-fold higher fatality rate was found among chronic 
HBsAg carriers than among patients without HBV infec-
tion.8 Furthermore, patients with chronic active hepatitis B 
or cirrhosis more likely have a worse outcome from HA 
than healthy HBsAg carriers.8 Acute HA, when occurring 
in patients with underlying chronic hepatitis C, may also 
cause significantly increased morbidity and mortality.9 In 
one study, fulminant HA was described in 41.2% of the 17 
HCV-infected patients, with a mortality rate of 35.3%.10 
Patients with other chronic liver diseases also appear to 
be at increased risk for more severe disease with superim-
posed HA.9 Fulminant hepatic failure during acute HA was 
described in patients who were injecting drug users and 
had alcoholic liver cirrhosis.11
To minimize the occurrence of acute HA in patients 
with chronic liver disease, a variety of organizations have 
recommended HA vaccination for these patients.9 The pre-
sent study aimed to verify the prevalence of HA immunity 
in patients with liver cirrhosis (LC), in a city of Southeastern 
Brazil, with the purpose of verifying a vaccination strategy 
against hepatitis A for these patients. 
METHODS
Between December 2005 and December 2006, 106 patients 
with LC were prospectively and consecutively evaluated at 
the Hospital de Clínicas da Universidade Federal de Uber-
lândia (HC-UFU), in the city of Uberlândia, state of Minas 
Gerais, Southeastern Brazil. 
A total of 82 (77.4%) of the evaluated patients were male 
and 24 (22.6%) were female; the mean age was 53.3 ± 11.9 years 
(age range from 22 to 87 years). Diagnosis of LC was based 
on liver biopsy, except in those patients whose coagulation 
disorders did not permit this type of test. In these cases, the 
diagnosis was based on clinical and laboratory criteria and 
on imaging tests (ultrasound and/or computed tomography). 
LC etiology was based on clinical history and specific lab-
oratory tests. The diagnosis of cryptogenic LC was made 
when no etiology could be identified. 
Most patients with LC evaluated had an alcoholic etiol-
ogy. In a previous work,12 alcoholics who sought treatment 
at the Alcohol Outpatient Clinic of the HC-UFU were found 
to have a high prevalence of serological markers of hepatitis 
B virus (HBV) and hepatitis C virus (HCV), and, as a result, 
they could also show higher seroprevalence of HAV infection. 
For this reason, although this study was not designed to be 
a case-control study, another group was also evaluated, with 
75 non-alcoholic individuals without evident chronic liver 
disease, who were cared for at the HC-UFU’s Department of 
Traumatology Outpatient Clinic. Of these, 55 (73.3%) were 
male and 20 (26.7%) were female; the mean age was 47.0 ± 
11.6 years (age range from 23 to 79 years). The positive or 
negative diagnosis of alcoholism was confirmed by clinical 
history and by the CAGE (Cutdown, Annoyed by criticism, 
Guilty and Eye-opener) questionnaire, which was applied to 
each patient to diagnose chronic abuse of or dependence on 
alcohol. CAGE was positive when two or more a! rmative re-
sponses were given to its four questions.13 
The minimum calculated sample size was 74 individuals, 
assuming a anti-HAV seroprevalence for the adult population 
in this region of 95%, error of 5% and 95% confidence.
Blood samples were subsequently collected from each 
patient who agreed to participate in the study and, after cen-
trifugation, serum was stored at -20oC. The technique used 
to detect hepatitis A serological markers were the use of mi-
croparticle enzyme immunoassay (Abbott, AxSYM system, 
Wiesbaden, Germany) for qualitative detection of total anti-
HAV (HAVAB 2.0) and IgM anti-HAV (HAVAB - M 2.0). 
One patient, who claimed to have been vaccinated against 
HA, was not included in the present study. This project was ap-
proved by the institutional research ethics committee and an 
informed consent form was signed by each patient for their par-
ticipation. Student’s t test was used to compare means of ages and 
Fisher’s exact test, to compare frequencies of immunity between 
both groups evaluated. A p < 0.05 was considered significant. 
RESULTS
The frequency of LC etiologies in males, females and global 
were, respectively: alcohol (64.6%, 37.5% and 58.5%); al-
cohol and HCV (14.6%, 0 and 11.3%); HBV (8.5%; 8.3% 
and 8.5%); HCV (3.7%, 12.5% and 5.7%); alcohol and HBV 
(2.4%; 4.2% and 2.8%), autoimmune hepatitis (0, 4.2% and 
0.9%); nonalcoholic steatohepatitis (0, 4.2% and 0.9%) 
and cryptogenic (6.1%, 29.2% and 11.3%). 
Patients with alcoholic LC, separately or associated with 
HBV or HCV, consumed 325 ± 214 g of ethanol per day and 
a minimum of 100 g/day, during a mean time of 28 ± 11 
years and a minimum of 10 years, and their CAGE question-
naire was positive. In the control group, the history of alco-
hol abuse and the results of the CAGE questionnaire were 
negative for all patients. 
Total anti-HAV was positive in 104/106 (98.1%) patients 
with LC and IgM anti-HAV was negative in all of them; 
in the control group, total anti-HAV was positive in 74/75 
(98.7%) individuals and IgM anti-HAV was positive in 1 
(p > 0.05) as shown in Table 1.
Oliveira, Comácio, Santos
270
Among patients with LC, 9 (8.5%) reported they had al-
ready had hepatitis and the LC etiologies in those patients 
were as follows: HBV in 4, HBV and alcohol in 2, HCV in 2 
and HCV and alcohol in 1; etiology (HBV) was confirmed 
by serological tests during acute illness in only one of them. 
In the control group, no patients remembered having had 
hepatitis. 
There was no significant di! erence in mean age between 
both groups evaluated. All individuals had a similar back-
ground. However, the frequency of monthly family income 
of up to three minimum wages was higher (p < 0.05) among 
patients with LC (80.4%) than among those of the control 
group (60.3%).
The ages of patients with LC and negative total anti-HAV 
were 50 years and 73 years, and the LC etiologies were alco-
hol and alcohol and HBV, respectively. The only individual 
in the control group with this negative test was 34 years old. 
DISCUSSION
No di! erences in frequencies of HA immunity were found 
between patients with LC and the control group. This is in 
agreement with reports stating that patients with chronic 
liver disease do not have higher risk of being infected with 
HAV than the general population.1 In addition, the control 
group was initially proposed to verify whether patients with 
LC of an alcoholic etiology had higher seroprevalence of 
HAV infection, as has been observed with regard to the virus 
of hepatitis B or C.12 Curiously, the only two patients with 
LC and negative anti-HAV had an alcoholic etiology. 
When patients with chronic liver disease acquire HAV 
infection, they have higher risk of fulminant hepatitis and 
death. The reason why patients with chronic liver disease 
have more frequent fulminant hepatitis during acute illness 
by HAV is not clear. It was speculated that acute HAV in-
fection may trigger autoimmune mechanisms in susceptible 
patients, which may increase liver damage due to hepatitis A 
and lead to massive necrosis of hepatocytes.10 During fulmi-
nant HA, people with chronic HBV infection were found to 
show transient appearance of anti-HBs and disappearance of 
HBsAg14 and, moreover, HBV DNA may become undetecta-
ble during the infection and again be detected after recovery 
from acute hepatitis A.10 In patients with chronic hepatitis C 
and fulminant hepatitis after HAV superinfection, serum 
HCV RNA can be undetectable during acute illness and 
become detectable again after these patients are cured of 
HA.10 The mechanism by which circulating viral markers 
are decreased is unknown; it is speculated that this may 
occur as a result of necrosis of hepatocytes harboring rep-
licating hepatitis virus.14
Thus, people who have chronic liver disease should be 
vaccinated against HAV. The response to HAV vaccination 
in chronic liver disease is optimal when aimed at patients 
before hepatic decompensation develops, i.e. in patients 
with chronic hepatitis or patients with liver cirrhosis Child-
Pugh class A, a 98% response rate was observed after full 
course of vaccination, compared with a rate of 65.7% in pa-
tients with decompensated liver disease.15
In the present study, the seroprevalence of HAV infec-
tion in patients with LC was as high as that observed in other 
developing countries, such as India, where, due to the high 
frequency of HA immunity among patients with LC, authors 
do not recommend routine vaccination.16,17 These results 
are also similar to those of another study, performed in pa-
tients with chronic HCV infection (median age of 50 years, 
age range from 4 to 81 years), in the state of Pernambuco, 
Northeastern Brazil, where HA immunity was observed in 
96% of patients. For this reason, authors of this study recom-
mend anti-HAV testing before vaccination against HAV as 
a cost-e! ective strategy.18 However, these results are higher 
Table 1. Frequency of antibodies against HAV in patients with liver cirrhosis and in the control group
Anti-HAV  Liver cirrhosis    Control group  p value*
  Male Female Total Male Female Total 
  n (%) n (%) n (%) n (%) n (%) n (%) 
IgM       
 Positive 0 0 0 0 1 (5) 1 (1.3) 0.41
 Negative 82 (100) 24 (100) 106 (100) 55 (100) 19 (95) 74 (98.7) 
Total       
 Positive 80 (97.6) 24 (100) 104 (98.1) 54 (98.2) 20 (100) 74 (98.7) 1.00
 Negative 2 (2.4) 0 2 (1.9) 1 (1.8) 0 1 (1.3) 
* Fisher’s exact test: liver cirrhosis group = control group 
HA immunity among Brazilian patients with liver cirrhosis
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than those observed in patients with HCV infection (mean 
age of 44.8 years), in the city of Rio de Janeiro (86%), leading 
authors of this other study to recommend implementation 
of hepatitis A vaccination for this population.19
Thus, despite the observed changes in the HA epidemiol-
ogy from high to intermediate endemicity in the Southeast-
ern Brazil, the high seroprevalence of anti-HAV antibod-
ies in adult patients with LC observed in the present study 
shows that routine HA vaccination could not be implement-
ed for this patients. In addition, the serological test for total 
anti-HAV detection by ELISA method is five times cheaper 
than complete vaccination against hepatitis A [R$ 35.00 
(US$ 19.4) versus R$ 180.00 (US$ 100), respectively], and, 
for these reasons, the screening for HAV antibody before 
vaccination could be recommended for adult patients with 
chronic liver disease due to its higher cost-e! ectiveness. 
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